Adjuvant FOLFIRINOX in Patients with Resectable Pancreatic Cancer Is Effective but Rarely Feasible in Real Life: Is Neoadjuvant FOLFIRINOX a Better Option?

SIMPLE SUMMARY: In this paper, we showed that only a minority of patients (23%) undergoing upfront pancreatic resection completed the planned 12 courses of FOLFIRINOX, and we delineated the reasons for not completing it. We showed that patients who received neoadjuvant treatment were significantly m...

Descripción completa

Detalles Bibliográficos
Autores principales: Maman, Yossi, Goykhman, Yaacov, Yakir, Oz, Barenboim, Alex, Geva, Ravit, Peles-Avraham, Sharon, Wolf, Ido, Klausner, Joseph M., Lahat, Guy, Lubezky, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252647/
https://www.ncbi.nlm.nih.gov/pubmed/37297011
http://dx.doi.org/10.3390/cancers15113049

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252647/
https://www.ncbi.nlm.nih.gov/pubmed/37297011
http://dx.doi.org/10.3390/cancers15113049

Ejemplares similares